מכפיל P/S עתידי: iCAD Corp (ICAD)
The forward P/S chart for iCAD, Inc. (ICAD) demonstrates the resilience of an asset shielded from macroeconomic volatility by stable demand for medtech. Growth is driven by the expansion of B2B subscriptions for AI software in radiology centers and partnerships with equipment behemoths. The mass adoption of early breast cancer detection systems is stimulating revenue. The value of 5.50 determines the current status of the sales valuation parameter.
פילוחים אנליטיים של חברת iCAD, Inc.
Patents and FDA approval for AI-driven breast cancer diagnostics create high barriers to entry for competitors, which is reflected in the forward P/S ratio of 5.50 for iCAD, Inc. (ICAD). This indicator is calculated as the ratio of market capitalization to projected revenue, allowing investors to assess the extent to which future sales expectations are priced in and determine the asset's degree of overboughtness.
